Mode of Administration: Intravenous infusion

2 trials

Sponsors

Intas Pharmaceuticals Ltd, Intas Pharmaceuticals Ltd Biopharma Division

Conditions

Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 1: C569- Malignant neoplasm of unspecifiedovary

Phase 3

A study to compare the efficacy and safety of INTP24 against AvastinÂ® in patients with lung cancer.

Active, not recruitingCTRI/2019/08/020665

Intas Pharmaceuticals Ltd Biopharma DivisionHealth Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung

Target: 594Updated: 2021-11-24

Unknown Phase

A comparative study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) in patients with a cancer of female organs that produce eggs

RecruitingCTRI/2018/01/011550

Intas Pharmaceuticals LtdHealth Condition 1: C569- Malignant neoplasm of unspecifiedovary

Target: 66Updated: 2021-11-24